Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gilead Sciences, Inc. < Previous 1 2 3 4 5 6 7 8 Next > Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma September 16, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19 September 16, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline September 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity September 13, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study September 07, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) September 06, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status September 04, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Present at Upcoming Investor Conferences August 29, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022 August 29, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option August 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care August 17, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Acquire Remaining Worldwide Rights of Trodelvy® August 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study August 15, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency August 09, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Acquire MiroBio August 04, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Announces Second Quarter 2022 Financial Results August 02, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection July 28, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) July 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19 July 22, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic July 21, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity July 20, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir) July 19, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 July 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel July 12, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma June 28, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor June 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases June 27, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV June 24, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks June 23, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022 June 21, 2022 From Gilead Sciences, Inc. Via Business Wire Tickers GILD < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.